共 21 条
[1]
Muller R., Pentoxifylline, a biomedical profile, J Med, 10, pp. 307-329, (1979)
[2]
Noz K.C., Korstanje M.J., Vermeer B.J., Ulcerating necrobiosis lipoidica effectively treated with pentoxifylline, Clin Exp Dermatol, 18, pp. 78-79, (1993)
[3]
Calderon M.J., Landa N., Aguirre A., Diaz-Perez J.L., Successful treatment of cutaneous PAN with pentoxifylline, Br J Dermatol, 128, pp. 706-707, (1993)
[4]
Wong S.S., Holt P.J.A., Generalized morphoea and primary biliary cirrhosis: a rare association and improvement with oxypentifylline, Clin Exp Dermatol, 17, pp. 371-373, (1992)
[5]
Wahba-Yahav A., Intractable chronic furunculosis: prevention of recurrences with pentoxifylline, Acta Derm Venereol, 72, pp. 461-462, (1992)
[6]
Schwarz A., Krone C., Trautinger F., Aragane Y., Neuner P., Luger T.A., Schwarz T., Pentoxifylline suppresses irritant and contact hypersensitivity reactions, J Investy Dermatol, 101, pp. 549-552, (1993)
[7]
Schwarz T., Schwarz A., Krone C., Luger T.A., Pentoxifylline suppresses allergic patch test reactions in humans, Arch Dermatol, 193, pp. 513-514, (1993)
[8]
Strieter R.M., Remick D.G., Ward P.A., Spengler R.N., Lynch J.P., Larrick J., Kunkel S.L., Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline, Biochem Biophys Res Commun, 155, pp. 1230-1236, (1988)
[9]
Alegre M.L., Gastaldello K., Abramowicz D., Kinnaert P., Vereerstraeten P., Pauw L., Vandenabeele P., Moser M., Leo O., Goldman M., Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome, Transplantation, 52, pp. 674-679, (1991)
[10]
Boogaerts M.A., Meeus P., Scheers W., Declercq M., Vande Broeck J., Verhoef G., Pentoxifylline and analogues: effects on normal and diseased granulocyte function in vitro, pp. 9-16, (1990)